Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...
The perception of GLP-1s — and the people who use them — is getting better, but work still must be done to avoid stigma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback